Monday Aug 18
Merck & Co. Stock Rating Reaffirmed by Zacks
's stock had its "neutral" rating reissued by Zacks in a note issued to investors on Monday.
Sat Aug 16, 2014
Hazardous Material Crews Responded to Merck and Company
U.S. factory output rose for the sixth consecutive month in July, led by a jump in the production of motor vehicles, furniture, textiles and metals.
Tue Aug 12, 2014
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies
Tumor cells that refuse to die have led researchers to develop immuno-oncology drugs, a brand new class, with Big Pharma participation.
Dow Movers: CVX, MRK
In early trading on Tuesday, shares of Merck & Co. topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.5%.
Mon Aug 11, 2014
Enanta Pharmaceuticals Is Simply Too Cheap To Ignore
Based on my conservative revenue estimates, I believe Enanta will easily double from current levels within the next 12 months.
Merck & Co. Price Target Cut to $60.00
Jefferies Group's target price indicates a potential upside of 6.10% from the stock's previous close.
Fri Aug 08, 2014
Small companies lead the I-O class of Cancer Therapies
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades.
Wed Aug 06, 2014
Gilead Is Going To Make More Money In The Future
Gilead Sciences is one of the more compelling companies on the market. Anyone who is familiar with the company is aware that Sovaldi is hailed as a cure for hepatitis C, and prevents the need for 'costly' alternatives such as a liver transplant.
Sat Aug 02, 2014
Merck & Co. PT Raised to $62.00 at BMO Capital Markets
BMO Capital Markets' price objective would suggest a potential upside of 9.15% from the stock's previous close.
Fri Aug 01, 2014
Job growth in July signals more progress
U.S. payrolls grew by 209,000 jobs in July - less than expected, but still enough to begin to erase the jobs deficit created by the recession, the U.S. Labor Department reported Friday.
Thu Jul 31, 2014
Merck & Co. Given "Neutral" Rating at Credit Suisse
's stock had its "neutral" rating reaffirmed by research analysts at Credit Suisse in a report released on Thursday.
Tue Jul 29, 2014
Tuesday Morning Earnings Releases
Arrow Electronics reported its Q2 2014 earnings. The company reported an EPS of $1.43, above estimates of $1.42, and revenue for the quarter of $2.68 billion compared to estimates of $5.69 billion.
Salt Lake Tribune
Merck's second-quarter profit more than doubles
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.
The Beaumont Enterprise
Merck 2Q profit more than doubles
In this Thursday, Feb. 28, 2013 photo, Merck scientist Pascale Nantermet conducts research to discover new HIV drugs in West Point, Pa.
Fri Jul 25, 2014
Merck to cut 600 jobs in Montco
Merck & Co., which is reorganizing to slash $2.5 billion in costs and 8,500 workers, has informed Pennsylvania officials that it will cut 600 jobs at facilities in North Wales and Lansdale.
Thu Jul 24, 2014
Merck Looks Overpriced Compared To This Sector Peer
We pitch two companies from the pharmaceutical sector, Merck and AbbVie, against one another in the latest installment of our Head-To-Head series.
Wed Jul 23, 2014
IPR Update -- The First Pharma IPR Decisions
Late last month, while many of us were getting ready to attend the BIO International Convention in San Diego, the Patent Trial and Appeal Board issued four related inter partes review opinions, marking what many have called the first set of opinions related to the Pharmaceutical industry.
Biopharma industry at highest risk for employee turnover
A new survey reveals it might be easier for companies in the biopharma industry to poach employees from one another, especially among employees who view themselves as underpaid.